Sanofi jumps on CAC 40 as analysts raise price targets
Sanofi shares are among the CAC 40's top gainers after several major banks raised their price targets following a stronger-than-expected third quarter. UBS, Baader Europe and Exane BNP Paribas all lifted targets, citing Dupixent's outperformance, while investors still watch for concrete plans beyond the immunology flagship.
Key Takeaways
- Sanofi traded near €85–€86 on November 9, topping the CAC 40 after breaking €84.53 resistance.
- UBS raised its target to €88 (Neutral); Baader Europe to €109 (Add); Exane BNP Paribas to €102 (Outperform).
- Dupixent drove Q3 strength, accounting for about 39.37% of group sales in the quarter.
- Analysts flag an almost empty pipeline and expect bold M&A or licensing to prepare for life after Dupixent.
- Shares are up roughly 7.55% over one week and 20.91% over one month.
Why are Sanofi shares rallying today?
According to MarketScreener, Sanofi was one of the CAC 40's biggest gainers on the morning of November 9, 2026, rising about 1.77% to €85.22 as analysts turned more constructive. Ideal Investisseur later reported the stock up 2.41% to €85.76, leading the index, which itself rose 0.36%.
The move pushed the shares through former resistance at €84.53, now acting as support. The stock has gained 7.55% over one week and 20.91% over one month after touching a multi-year low in early October. Next technical resistance sits at €89.89, though an RSI near 80 points to an overbought setup.
For more market and wealth coverage, see our Net Worth & Wealth hub.
Which banks raised Sanofi price targets?
UBS said Sanofi's Q3 report was significantly above expectations, led by Dupixent, which generated 39.37% of group sales between July and September. The Swiss bank highlighted operating leverage, productivity gains in G&A and contained R&D spending, which amplified EBIT from operations by 26%. UBS remains Neutral but raised its price target from €78 to €88.
Baader Europe kept an Add rating and lifted its target from €104 to €109, noting that growth has leaned heavily on Dupixent, with some support from rare-disease medicines and insulins. Exane BNP Paribas upgraded from Neutral to Outperform and raised its target from €79 to €102, implying about 19% upside versus the then-current price, Ideal Investisseur reported. Barclays also raised its target in early November.
Full analyst commentary is detailed in the MarketScreener report.
What risks remain after Dupixent's strong quarter?
UBS warned that Sanofi's pipeline is practically empty and that replacing Dupixent grows harder the larger the franchise becomes. Management has signaled that the answer will involve significant mergers and acquisitions or licensing deals. UBS estimates roughly €35bn to €40bn could be deployed if Sanofi lifted its 2028 net debt-to-EBITDA ratio to 3x.
Conference-call takeaways included expectations that Dupixent's outperformance will moderate, plans to adjust Phase 3 protocols to raise success odds, and more aggressive price competition from Merck on Beyfortus than expected—though vaccines should rebound in Q4 on late flu deliveries. The group raised its 2026 targets on October 30 after a third quarter up 14.3%, driven by Dupixent.
Simply Wall St separately noted that statutory profit was reduced by €4.7bn due to unusual items in the year to September 2026, so underlying earnings power may look stronger than headline profit, even as EPS shrank over twelve months. Consensus multiples cited by Ideal Investisseur put the stock near 9.6 times current-year earnings and 9.2 times next-year earnings.